Cancer treatment reviews最新文献

{"title":"Long-term surveillance recommendations for young adult cancer survivors","authors":"Katharina Egger-Heidrich ,&nbsp;Franziska Wolters ,&nbsp;Mareike Frick ,&nbsp;Teresa Halbsguth ,&nbsp;Theresa Müller ,&nbsp;Hannah Woopen ,&nbsp;Kristin Tausche ,&nbsp;Diana Richter ,&nbsp;Judith Gebauer","doi":"10.1016/j.ctrv.2025.102992","DOIUrl":"10.1016/j.ctrv.2025.102992","url":null,"abstract":"<div><h3>Background</h3><div>Advancements in cancer treatment have led to increased survival rates among young adult cancer survivors (YACS). However, these individuals face unique long-term health risks, including secondary malignancies, cardiovascular disease, and psychosocial challenges. Effective long-term surveillance strategies are critical to mitigating these risks and improving health outcomes. This scoping review aims to summarize existing recommendations for long-term surveillance of YACS, identify gaps in current guidelines, and highlight areas for future research.</div></div><div><h3>Methods</h3><div>A scoping review was conducted using Pubmed focusing on peer-reviewed literature published between January 2015 and January 2025 that addresses post-treatment (&gt;5 years after diagnosis) follow-up strategies for YACS. The review synthesizes recommendations across various cancer types, treatment modalities, and long-term effects.</div></div><div><h3>Results</h3><div>The review identified 32 recommendations. Of all eligible articles initially retrieved, 169 different articles were included after screening and eligibility. Findings indicate a lack of standardized, age-specific surveillance guidelines, with most recommendations adapted from pediatric or adult oncology frameworks. Emerging evidence suggests that risk-based, personalized surveillance approaches—incorporating genetic predisposition, treatment history, and lifestyle factors—may optimize long-term health outcomes.</div></div><div><h3>Discussion</h3><div>This review underscores the need for age-appropriate, evidence-based surveillance guidelines tailored to YACS and highlights the importance of multidisciplinary care models to support survivorship. Future research should focus on developing standardized, risk-stratified surveillance protocols and evaluating their impact on health outcomes.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"139 ","pages":"Article 102992"},"PeriodicalIF":9.6,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144606174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"T-cell engager toxicity in clinical phase trials; A systematic review and meta-analysis","authors":"Zoulikha M. Zaïr ,&nbsp;Gemma Butterworth ,&nbsp;Mariam Shalaby ,&nbsp;Eduard Oštarijaš ,&nbsp;Fiona Thisthlethwaite","doi":"10.1016/j.ctrv.2025.102991","DOIUrl":"10.1016/j.ctrv.2025.102991","url":null,"abstract":"<div><div>Engineered to activate a patient’s own immune response, T Cell Engagers (TCEs) are positioned to mediate T cell directed cytotoxicity through targeted engagement of a tumour antigen. Despite their attractive properties TCE therapies have yet to be widely used in the treatment of solid tumours with several obstacles that include adverse toxicity profiles.</div><div>This systematic review and <em>meta</em>-analysis assessed the toxicity associated with T-cell engagers (TCEs) in the treatment of solid tumours. Papers were sourced from MEDLINE, Cochrane Library, CINHL, EMBASE, Web of Knowledge, Scopus. Prevalence data from the identified primary studies was pooled using an inverse variance method with a restricted maximum likelihood estimator. Freeman-Tukey double arcsine transformation to determine toxicity prevalence and confidence intervals.</div><div>A total of 1147 publications were identified of which 30 were included for systematic review. Toxicity profiles from 17 TCEs, comprising 9 different ligands that utilised the CD3, CD40, CD28 or CD64 signalling pathways were characterised in this study. Of these studies, 21 publications were included for <em>meta</em>-analysis, focussing on four TCEs: catumaxomab, ertumaxomab, tebentafusb, and MDX-H210. Meta-analysis found that the most prevalent toxicities were gastrointestinal and inflammatory. Subgroup analysis revealed that Gastrointestinal toxicity (GI) toxicity was independent of tumour type or ligand. Cytokine Release Syndrome (CRS) is potentially being under-reported due to challenges of differentiation of CRS from other inflammatory mediated constituent symptoms, although Fc-independent TCEs were linked to lower inflammatory toxicity. The review highlights TCE-dependent toxicity profiles and highlights key features that may ameliorate TCE tolerance.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"139 ","pages":"Article 102991"},"PeriodicalIF":9.6,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144588857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A systematic review of phase I trials in patients with ovarian cancer","authors":"Giuliana Pavone ,&nbsp;Federica Martorana ,&nbsp;Vincenza Ricco ,&nbsp;Esteban Andres Ciliberti ,&nbsp;Marta Nerone ,&nbsp;Cristiana Sessa ,&nbsp;Ilaria Colombo","doi":"10.1016/j.ctrv.2025.102982","DOIUrl":"10.1016/j.ctrv.2025.102982","url":null,"abstract":"<div><h3>Background</h3><div>Ovarian cancer (OC) is the leading cause of death among gynecological malignancies, with limited treatment options for advanced and platinum-resistant disease. This systematic review analyzes phase I trials to assess recent therapeutic advancements.</div></div><div><h3>Methods</h3><div>We performed a systematic review of phase I trials in OC, published between 2012 and 2023, retrieving data on trial characteristics and outcomes. Studies were classified according to the tested treatment strategies into chemotherapy-only (CO), chemotherapy + non-chemotherapy agents (CNC) and chemotherapy-free (CF).</div></div><div><h3>Results</h3><div>78 trials were included, with more than 50 % of them published in the last four years. Overall, chemotherapy and immunotherapy were the most investigated agents. Fourteen trials (17.9 %) evaluated a CO strategy, 42 (53.8 %) a CNC combination and 22 (28.2 %) a CF therapy. Dose-limiting toxicities and toxic deaths were observed in 71 % and 100 % of CO studies, in 45.2 % and 21 % of CNC trials and in 37.4 % and 13.6 % of CF trials, respectively. CNC regimens outperformed the other treatment types in terms of efficacy outcomes, including overall response rate (11.5 % CO; 32.2 % CNC; 25.5 % CF), clinical benefit rate (40 % CO; 62 % CNC; 52 % CF) and median progression free survival (mPFS 5.9 months CO; 6.45 months CNC; 4.85 months CF). Trials enrolling platinum resistant or agnostic patients displayed worse clinical outcomes.</div></div><div><h3>Conclusions</h3><div>In the last years, there has been an increasing number of phase 1 trials assessing new agents and new combinations in patients with OC. Chemotherapy-free strategies display a more favorable safety profile, while regimens combining CNC agents seem to be more effective compared to CO approaches.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"139 ","pages":"Article 102982"},"PeriodicalIF":9.6,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144502652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgical tumor volume reduction in patients with brain metastases: A systematic review and meta-analysis","authors":"Vittorio Stumpo ,&nbsp;Alessandro Carretta ,&nbsp;Jacopo Bellomo ,&nbsp;Luis Padevit ,&nbsp;Victor Staartjes ,&nbsp;Nicolai Maldaner ,&nbsp;Penelope Coker ,&nbsp;Jorn Fierstra ,&nbsp;Michael Weller ,&nbsp;Emilie Le Rhun ,&nbsp;Marcus Czabanka ,&nbsp;Oliver Bozinov ,&nbsp;Luca Regli ,&nbsp;Marian Christoph Neidert ,&nbsp;Carlo Serra ,&nbsp;Stefanos Voglis","doi":"10.1016/j.ctrv.2025.102981","DOIUrl":"10.1016/j.ctrv.2025.102981","url":null,"abstract":"<div><h3>Background</h3><div>Microsurgical resection of brain metastases (BM) has traditionally been a mainstay of local control for large or symptomatic lesions. Maximal tumor burden reduction remains controversial in the multidisciplinary management of BM patients and needs to be re-evaluated in view of new systemic treatment options. We conducted a systematic review and <em>meta</em>-analysis to evaluate the role of extent of resection (EOR)/residual volume (RV) for progression-free (PFS) and overall survival (OS) in patients with BM.</div></div><div><h3>Methods</h3><div>A systematic review was performed according to PRISMA guidelines and included studies’ quality was assessed with the Grading <em>of Recommendations,</em> Assessment<em>, Development, and</em> Evaluations (GRADE) tool. Study characteristics were tabulated and critically reviewed. Results from Cox-regression models and log-rank tests for the association of gross total resection (GTR) versus subtotal resection (STR) with PFS and OS were extracted to perform separate random-effects <em>meta</em>-analyses.</div></div><div><h3>Results</h3><div>Thirty-nine articles were included, all of them being retrospective and all but 3 monocentric. Most studies included BM from heterogenous primary tumors, with 9 focusing on BM from a single primary. Systemic therapies were variably reported and only 2 studies reported on the use of steroids. Twenty-one studies showed a significant association of EOR/RV with improved OS. Meta-analysis of studies reporting multivariable Cox-regression models (n = 11) showed a significant association of GTR with longer OS (HR 0.67, 95 %CI 0.56–0.81, p &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>Although in several studies higher EOR/lower RV was associated with improved OS, evidence consists of heterogeneous cohorts and rarely includes primary tumor-specific systemic therapies or relevant confounding covariates. New studies are needed to elucidate the role of microsurgical tumor burden reduction in BM patients in the era of targeted or immune modulatory therapies.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"139 ","pages":"Article 102981"},"PeriodicalIF":9.6,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144338812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PREDICTIVE BRCA GENETIC TESTING IN ITALIAN PATIENTS WITH BREAST CANCER: A POSITION PAPER OF ITALIAN SCIENTIFIC SOCIETIES [Italian Association of Medical Oncology(AIOM); Italian Association of Radiotherapy and Clinical Oncology (AIRO); Italian National Association of Breast Surgeons (ANISC); Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP); Italian Society of Surgical Oncology (SICO); Italian Society of Human Genetic (SIGU); Italian Society of General Practice (SIMG); Italian Society of Medical and Interventional Radiology (SIRM)]","authors":"L. Cortesi ,&nbsp;F. Miglietta ,&nbsp;L. Arecco ,&nbsp;D. Bernardi ,&nbsp;L. Biganzoli ,&nbsp;L. Del Mastro ,&nbsp;MV. Dieci ,&nbsp;J. Foglietta ,&nbsp;L. Fortunato ,&nbsp;P. Franco ,&nbsp;E.Lucci Cordisco ,&nbsp;P. Mantellini ,&nbsp;C. Marchio’ ,&nbsp;B. Meduri ,&nbsp;G. Micallo ,&nbsp;A. Musolino ,&nbsp;A. Salvetti ,&nbsp;D. Turchetti ,&nbsp;A. Zambelli ,&nbsp;C. Angiolini ,&nbsp;S. Gori","doi":"10.1016/j.ctrv.2025.102976","DOIUrl":"10.1016/j.ctrv.2025.102976","url":null,"abstract":"<div><div>The introduction of Poly (ADP-ribose) Polymerase (PARP) inhibitors in both metastatic and early-stage breast cancer (BC) treatment has led to the emergence of Mainstreaming Cancer Genetics (MCG) as a new approach to genetic counselling, predictive of therapy outcomes. Therefore, the <em>BRCA</em> testing criteria for therapeutic purposes require further implementation. This position paper outlines the Italian indications for predictive genetic testing, approved by a multidisciplinary Expert Panel representing major scientific societies involved in BC treatment in Italy.</div><div>We utilized the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach, and framed clinical questions as population, intervention, comparison and outcome (PICO). The final recommendations were determined through a voting process, covering key topics such as eligibility criteria for onco-genetic counselling, the role of contralateral prophylactic mastectomy (CPM) in patients harboring <em>BRCA1/2</em> germline pathogenic variants (gPV), and the positioning of predictive <em>BRCA1/2</em> test.</div><div>As results, the Expert Panel defined three distinct patient groups eligible for onco-genetic counselling, based on the <em>a priori</em> likelihood of carrying a gPV and the purpose of testing (predictive vs preventive). A conditional recommendation in favor of CPM in patients with a history of surgically treated BC and a <em>BRCA</em> gPV was suggested. Finally, a multidisciplinary pathway for <em>BRCA</em> testing was proposed, for patients with triple negative and hormone receptor-positive (HR+)/HER2-negative (HER2−) BC.</div><div>In conclusion, the predictive <em>BRCA</em> testing inside the onco-genetic framework marks an important step-forward in BC management. However, the integration of somatic testing, digital pathology, and artificial intelligence-driven models could refine patient selection for tailored treatments.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"139 ","pages":"Article 102976"},"PeriodicalIF":9.6,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144330689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overcoming Resistance to CDK4/6 inhibitors in Hormone Receptor positive, HER2 negative breast cancer: Innovative Combinations and Emerging Strategies","authors":"Federica Giugliano ,&nbsp;Carmine De Angelis ,&nbsp;Barbara Pistilli ,&nbsp;Giulia Viale ,&nbsp;Giampaolo Bianchini ,&nbsp;Mario Giuliano ,&nbsp;Luca Malorni ,&nbsp;Beatrice Taurelli Salimbeni ,&nbsp;Angela Esposito ,&nbsp;Antonio Giordano ,&nbsp;Timothy A. Yap ,&nbsp;Giuseppe Curigliano ,&nbsp;Carmen Criscitiello","doi":"10.1016/j.ctrv.2025.102980","DOIUrl":"10.1016/j.ctrv.2025.102980","url":null,"abstract":"<div><div>Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in combination with endocrine therapy (ET) improve outcomes patients affected by metastatic and early-stage hormone receptor-positive, HER2-negative breast cancer. However, approximately 20% of these tumors exhibit intrinsic resistance to such therapies, and most develop acquired resistance mechanisms that drive progression. Biomarker analyses of biological samples from patients treated with CDK4/6i plus ET have identified potential targets for therapeutic combinations. In this review, we discuss the mechanisms of action and resistance to CDK4/6i, providing a comprehensive overview of emerging efficacy and safety data, biomarker-driven strategies, and ongoing clinical trials. Finally, we delineate key research priorities aimed at guiding the development of innovative therapeutic combinations.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"139 ","pages":"Article 102980"},"PeriodicalIF":9.6,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144330688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancements in liquid biopsy for breast Cancer: Molecular biomarkers and clinical applications","authors":"Peng Qiu ,&nbsp;Xiaopeng Yu ,&nbsp;Fushuang Zheng ,&nbsp;Xi Gu ,&nbsp;QianQiu Huang ,&nbsp;Ke Qin ,&nbsp;Yueting Hu ,&nbsp;Bowen Liu ,&nbsp;Tianming Xu ,&nbsp;Tao Zhang ,&nbsp;Guanglei Chen ,&nbsp;Yang Liu","doi":"10.1016/j.ctrv.2025.102979","DOIUrl":"10.1016/j.ctrv.2025.102979","url":null,"abstract":"<div><div>Breast cancer is characterized by significant molecular heterogeneity; therefore, there are distinct clinical features, treatment modalities, and prognostic outcomes across its various molecular subtypes. In the era of precision medicine, liquid biopsy has emerged as a convenient and minimally invasive technique capable of dynamically representing the comprehensive tumor gene spectrum. This review systematically elaborates the clinical value of liquid biopsy as a breakthrough tool for precision diagnosis and treatment in breast cancer through dynamic detection of key biomarkers, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and non-coding RNA (ncRNA). Specific genetic mutations and methylation signatures in ctDNA can be applied to early breast cancer screening, minimal residual disease monitoring, and tracking drug resistance mechanisms. CTCs enumeration (≥1/7.5 mL in early-stage cancer or ≥ 5/7.5 mL in metastatic cancer) and PD-L1 expression levels demonstrate direct correlations with prognostic stratification and the efficacy of immunotherapy. As the specificity and sensitivity of liquid biopsy continue to improve, personalized treatment strategies, informed by biomarker analysis and targeted precision therapies, have unveiled new avenues of hope for patients with breast cancer. However, several challenges persist in the practical application of liquid biopsy. Despite persistent challenges, such as insufficient standardization and difficulties in resolving low-abundance variants, future advancements should focus on multi-omics integration and AI-driven technological breakthroughs to overcome bottlenecks in clinical translation. This review summarizes cutting-edge liquid biopsy technologies for identifying clinically significant molecular biomarkers, focusing on discussing critical challenges in the strategies to advance precision oncology applications for optimized treatment guidance and disease surveillance in breast cancer.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"139 ","pages":"Article 102979"},"PeriodicalIF":9.6,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144321570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic literature review of intravenous versus subcutaneous administration of oncology therapies: A clinical, economic and patient perspective","authors":"Saby George ,&nbsp;Maria T. Bourlon ,&nbsp;Michael J. Overman ,&nbsp;Matt Dixon ,&nbsp;Karishma Shelley ,&nbsp;Kristen J. Markus ,&nbsp;Rachel M. Kewley ,&nbsp;Sophie I. Pope ,&nbsp;Laurence Albigès","doi":"10.1016/j.ctrv.2025.102974","DOIUrl":"10.1016/j.ctrv.2025.102974","url":null,"abstract":"<div><div>Subcutaneous (SC) formulations of oncology therapies offer a potentially less time-consuming and more convenient alternative to intravenous (IV) administration. However, exploring the potential benefits of SC over IV administration from a broader perspective is necessary to understand the larger-scale impact. In this systematic literature review (SLR), we evaluated the efficacy, pharmacokinetics/pharmacodynamics (PK/PD), safety, and patient and healthcare provider (HCP) preference for SC/IV oncology therapies, along with differences in patient outcomes, costs, and time requirements. The SLR was conducted in January 2019 and updated in May 2023, and included 169 publications. Studies providing comparative results between IV and SC formulations regarding clinical, economic, and patient outcomes were included. The focus was anticancer therapies for which both IV and SC formulations are being developed in phase 3 clinical trials, or are regulatory approved. SC administration was associated with savings in HCP time and patient chair time. Direct and indirect cost-savings were also observed. Increased treatment satisfaction and patient/HCP preference was reported with SC administration, as was improved caregiver productivity. The relative tolerability of SC and IV formulations for oncology drugs was similar; however, a higher incidence of injection-site reactions was reported with SC administration. Overall survival, PK/PD, and overall response rate results were comparable between IV and SC administration. This SLR demonstrates that SC and IV administration had comparable efficacy, PK/PD, and tolerability profiles, with SC administration associated with cost and time savings, and generally preferred by patients and HCPs. Therefore, SC administration of oncology therapies may offer advantages over IV administration.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"139 ","pages":"Article 102974"},"PeriodicalIF":9.6,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144513968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunocytokines in cancer treatment: A systematic review","authors":"Stefano Agliardi ,&nbsp;Chiara Veronese ,&nbsp;Ferdinando Panzeri ,&nbsp;Simonetta Palazzini ,&nbsp;Greta Guarnieri ,&nbsp;Stefano Loiacono ,&nbsp;Vanessa Martinelli ,&nbsp;Anna Maria Potenza ,&nbsp;Emanuele Sbraga ,&nbsp;Eleonora Rissotto ,&nbsp;Elvira Inglese ,&nbsp;Federica Tosi ,&nbsp;Federica Villa ,&nbsp;Giorgio Patelli ,&nbsp;Letizia Monti ,&nbsp;Arianna Pani ,&nbsp;Romano Danesi ,&nbsp;Diego Fornasari ,&nbsp;Salvatore Siena ,&nbsp;Andrea Sartore-Bianchi","doi":"10.1016/j.ctrv.2025.102978","DOIUrl":"10.1016/j.ctrv.2025.102978","url":null,"abstract":"<div><h3>Introduction</h3><div>Immunocytokines are an emerging class of antibody-cytokine fusion proteins combining the specificity of monoclonal antibodies with the potent immunostimulatory effects of cytokines, potentially enhancing the anti-tumor immune response while reducing systemic toxicity.</div></div><div><h3>Methods</h3><div>We conducted a systematic review following the PRISMA guidelines<strong>.</strong> We performed a comprehensive literature search using PubMed and <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> databases. The search strategy included the terms “immunocytokine”, “cytokine”, “tumor”, and “cancer”. Filters were applied to retrieve only peer-reviewed articles and clinical trials.</div></div><div><h3>Results</h3><div>25 publications were retrieved: 15 were Phase I studies; 2 Phase I/II, and 8 Phase II. Regarding ongoing clinical trials, 62 studies were included: 30 were Phase I studies, 2 Phase III, and the remaining 30 were either Phase II (n = 13) or Phase I/II (n = 17). In 50/62 trials, the primary and co-primary outcomes included safety measures, such as adverse effects, dose-limiting toxicities, and maximum tolerated dose. In both studies from literature and ongoing clinical trials, the most common target was extra-domain B (EDB) of fibronectin, and the most investigated type of cancer was melanoma. While all published studies focused on solid tumors, several ongoing trials include hematologic malignancies.</div></div><div><h3>Conclusions</h3><div>Research interest in immunocytokines as a potential cancer treatment is increasing, although only limited data are currently available. Several trials, mainly in the early phase, are ongoing, paving the way for a possible broader clinical application of this class of immunotherapeutics.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"139 ","pages":"Article 102978"},"PeriodicalIF":9.6,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144338813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clearer Horizons: The latest advances in clear cell ovarian cancer treatment","authors":"Felix Blanc-Durand ,&nbsp;Natalie Ngoi ,&nbsp;Diana Lim ,&nbsp;Isabelle Ray-Coquard ,&nbsp;David SP Tan","doi":"10.1016/j.ctrv.2025.102977","DOIUrl":"10.1016/j.ctrv.2025.102977","url":null,"abstract":"<div><div>This review aims to consolidate the current understanding of Clear Cell Ovarian Carcinoma (CCOC), a rare yet distinct subtype of epithelial ovarian cancer. CCOC exhibits unique epidemiological, clinical and molecular features, being one of the most frequent subtypes in East Asia, often diagnosed at an early stage and frequently affecting younger women.</div><div>Its hallmark characteristics include high resistance to conventional chemotherapy, poor prognosis in advanced stage and a molecular profile distinct from high-grade serous histotype. Specifically, CCOC is characterized by a low prevalence of <em>TP53</em> mutations, <em>BRCA1/2</em> mutations and homologous-recombination deficiency, but a high frequency of <em>ARID1A</em>, along with other SWI/SNF alterations, and <em>PIK3CA</em> mutations, both of which represent promising therapeutic targets.</div><div>Despite the absence of validated therapies for CCOC so far, significant advancements in preclinical research and emerging clinical strategies including immunotherapy combinations offer hope for improved outcomes. Given the rarity of this cancer type, collaborative research and global partnerships have enabled robust studies and the implementation of trials with innovative personalized therapeutic approaches.</div><div>The objective of this report is to explore the epidemiology, clinical and molecular characteristics, current standard of care and evolving therapeutic strategies for CCOC patients. It will not only highlight the progress made so far, but most importantly identifies critical research priorities to optimizing patient outcomes.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"138 ","pages":"Article 102977"},"PeriodicalIF":9.6,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144280374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}